Congenital Heart Disease: The State-of-the-Art on Its Pharmacological Therapeutics.

ABSTRACT: Congenital heart disease is one of the most common causes of death derived from malformations. Historically, its treatment has depended on timely diagnosis and early pharmacological and surgical interventions. Survival rates for patients with this disease have increased, primarily due to advancements in therapeutic choices, but mortality remains high. Since this disease is a time-sensitive pathology, pharmacological interventions are needed to improve clinical outcomes. Therefore, we analyzed the applications, dosage, and side effects of drugs currently used for treating congenital heart disease. Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, and potassium-sparing diuretics have shown a mortality benefit in most patients. Other therapies, such as en

SUBMITTER: Varela-Chinchilla CD 

PROVIDER: S-EPMC9316572 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature